Literature DB >> 16062081

Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.

Sue S Yom1, Mitchell Machtay, Merrill A Biel, Robert J Sinard, Adel K El-Naggar, Randal S Weber, David I Rosenthal.   

Abstract

OBJECTIVES: Patients who have received definitive radiation therapy (RT) for a nonlaryngeal T3/4 head and neck squamous cell carcinoma have a limited opportunity for post-RT surgical salvage. The authors reviewed the practice of planned post-RT restaging to determine its impact on the success of early surgical salvage.
METHODS: A retrospective review was performed for patients with resectable T3/4 cancers of the oropharynx and hypopharynx treated with RT +/- chemotherapy who underwent planned restaging clinically, radiographically (CT or MRI), and by direct laryngoscopy with biopsy at 4 to 8 weeks post-RT. Chemotherapy was given as induction, concurrently, or both. Neck dissection was performed at time of restaging in patients with primary tumor control and initial N2/N3 neck disease or persistent lymphadenopathy.
RESULTS: A total of 54 patients had a median follow-up of 34.7 months (range, 7.6-97.8 months). Forty-two patients (78.8%) achieved a complete response (CR) at the primary site immediately after RT. Six developed late local failure at 9 to 61 months, of whom 2 were successfully salvaged. The ultimate 2-year local control among patients with initial CR was 94.8%. The 2-year organ preservation, disease-free survival, and overall survival (OS) rates were was 92.5%, 87%, and 90%, respectively. Twelve patients did not achieve initial CR. Two patients with bulky stage IV disease had unresectable cancers. Ten underwent immediate surgical salvage and 7 achieved local control (1 of whom developed distant metastases) whereas 3 had continued local failure. For patients without initial CR, the 2-year ultimate local control rate was 46.7% and OS was 46.8%. For all patients, overall 2-year local control, organ preservation, and OS rates were 85.6%, 75.6%, and 81.8% respectively. The rate of local failure-free organ preservation was 71.5%.
CONCLUSION: For patients with T3/4 resectable nonlaryngeal head and neck cancers, planned clinical, radiographic, and pathologic restaging at 1 to 2 months after definitive RT provides the opportunity for early surgical salvage in those who fail at the primary site. This practice produces improved overall local control and survival rates compared with the literature reports for delayed attempted salvage with timing based on the findings of routine postradiation clinical surveillance. Future efforts may focus on the improved selection of patients who would be most likely to require early surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16062081     DOI: 10.1097/01.coc.0000162422.92095.9e

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  17 in total

1.  Role of narrow-band imaging and high-definition television in the surveillance of head and neck squamous cell cancer after chemo- and/or radiotherapy.

Authors:  Cesare Piazza; Daniela Cocco; Luigi De Benedetto; Francesca Del Bon; Piero Nicolai; Giorgio Peretti
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-03-30       Impact factor: 2.503

Review 2.  Assessment of treatment response after chemoradiation of head and neck cancer.

Authors:  Fernando Luiz Dias
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

3.  Detection of Local Recurrence in Patients with Head and Neck Squamous Cell Carcinoma Using Voxel-Based Color Maps of Initial and Final Area under the Curve Values Derived from DCE-MRI.

Authors:  J Y Lee; K L Cheng; J H Lee; Y J Choi; H W Kim; Y S Sung; S R Chung; K H Ryu; M S Chung; S Y Kim; S-W Lee; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2019-07-18       Impact factor: 3.825

4.  Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands.

Authors:  Charlotte S Schouten; Otto S Hoekstra; C René Leemans; Jonas A Castelijns; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-06       Impact factor: 2.503

5.  Applications of diffusion-weighted magnetic resonance imaging in head and neck squamous cell carcinoma.

Authors:  Vincent Vandecaveye; Frederik De Keyzer; Piet Dirix; Maarten Lambrecht; Sandra Nuyts; Robert Hermans
Journal:  Neuroradiology       Date:  2010-07-15       Impact factor: 2.804

6.  Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer.

Authors:  John P Kostrzewa; William P Lancaster; Tim A Iseli; Renee A Desmond; William R Carroll; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2010-02       Impact factor: 3.325

7.  Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors.

Authors:  Jason T Rich; Simon Milov; James S Lewis; Wade L Thorstad; Douglas R Adkins; Bruce H Haughey
Journal:  Laryngoscope       Date:  2009-09       Impact factor: 3.325

8.  Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma.

Authors:  Hidenori Inohara; Keisuke Enomoto; Yoichiro Tomiyama; Ichiro Higuchi; Takehiro Inoue; Jun Hatazawa
Journal:  Mol Imaging Biol       Date:  2009-05-07       Impact factor: 3.488

9.  Salvage Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent Chemoradiotherapy Case Series and Review of the Literature.

Authors:  Patricia L Kearney; John M Watkins; Keisuke Shirai; Amy E Wahlquist; John A Fortney; Elizabeth Garrett-Mayer; M Boyd Gillespie; Anand K Sharma
Journal:  Mcgill J Med       Date:  2011-06

10.  Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.

Authors:  Marcus M Wagner; Joel K Curé; Jimmy J Caudell; Sharon A Spencer; Lisle M Nabell; William R Carroll; James A Bonner
Journal:  Radiat Oncol       Date:  2012-12-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.